Business - Sharing Value? GALVmed Case Study


Published on

Published in: Business, Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Business - Sharing Value? GALVmed Case Study

  1. 1. Stuart Brown<br />Communications Manager<br />Presented at Business - Sharing Value? 20th September 2011, Edinburgh<br />A NIDOS event<br />GALVmedSeptember~ NIDOS<br />
  2. 2.
  3. 3. What is GALVmed?<br /><ul><li>The Global Alliance for Livestock Veterinary Medicines
  4. 4. A Private Public Partnership
  5. 5. Funded internationally, taking research from wherever it is best in the world seeking, where practicable, to produce and deliver from within Africa and South Asia
  6. 6. Short term achievable goals, small footprint, driven by sustainability</li></ul>We are currently funded by the Bill and Melinda Gates Foundation, DFID and the European Union <br />
  7. 7. What is our focus?<br /><ul><li>To make a sustainable difference in the access to animal health medicines by poor livestock keepers (in support of the MDGs)‏
  8. 8. To develop, register and launch 4 to 6 vaccine, pharmaceutical or diagnostic products by 2015 ( minimum targets)‏
  9. 9. To work with partner agencies in developing countries to ensure sustainable research, production and delivery of these new products to poor livestock keepers</li></li></ul><li>Challenges to availability of appropriate new products<br />Discovery Research<br />Development<br />Registration<br />Production<br />Commer-cialisation<br />Sustained delivery<br />Unclear and varied regulatory requirements. <br />Lack of QA/QC.<br />Multiple regulatory authorities.<br />Inconsistent supply<br />Counterfeit products.<br />Lack of patent protection.<br />Poor quality and efficacy.<br />Technical challenges. <br />Lack of appropriate product profiles<br />Ill-designed proofs-of-concept<br />Lack of funding for development studies - high risk, <br />high cost.<br />Poorly designed, poorly controlled<br />field trials.<br />Lack of market pull-through<br />Poor estimates of need or demand<br />Inappropriate pack-sizes<br />Lack of knowledge or education on proper use<br />No commercial interest<br />Expensive processes<br />No process development<br />Our role is to facilitate leadership to overcome these challenges through creating partnerships <br />
  10. 10. Some of our Alliance members and operational partners<br /><ul><li>FAO, OIE, African Union IBAR European Commission,‏ Government of India, State of Haryana
  11. 11. Farm Africa, Africare, Vetaid, Land O Lakes,Mercy Corps, ILRI, BAIF
  12. 12. DIFD, Bill and Melinda Gates Foundation , European Union
  13. 13. Pfizer, Merial, Intervet, CEVA, Indian Immunological, NVI, CTTBD, OBP
  14. 14. OVI,( RSA), CIRAD, (France) NVI(Ethiopia) Universities of Melbourne, Queensland, Makerere, Sokoine,(TZ) Basle, Edinburgh, Pretoria, TANUVAS ,</li></li></ul><li>The growing reach of an Alliance<br />Product development partners:<br />Europe<br />Asia<br />North & Latin America<br />Australia<br />Enabling Activities:<br /><ul><li>14 African countries (East, Central, Western & Southern Africa)
  15. 15. India & Nepal</li></li></ul><li>A Voice Empowers the Poor<br />Tabitha Maunder, Women's Dairy Goat Project, Mwingi, Kenya<br />“ Before I became a buck keeper, I would never even be acknowledged or invited to a public meeting. Now I am not just invited but even given the opportunity to speak. I have been lifted from the ground to somewhere.”<br />
  16. 16. Business focus<br />Objective 1<br />Develop data driven decision making tools for socio economic impact and understanding of markets<br />Objective 2<br />Developing 4 vaccines for 6 animal health diseases critical to poverty reduction<br />Central Skills<br />Leadership, <br />Focus <br />Strategy <br />Partnership<br />Portfolio Development<br />Resourcing <br />Monitoring + Evaluation<br />Objective 3<br />Addressing Adoption Access Supply, creating value chains, defining sustainability <br />Objective 4<br />Communicate + network at all levels to gain buy in to paradigm change<br />
  17. 17. Animal Health Industry<br />Governments<br />Pro Poor Impact through sustainable Animal Health<br />GALVmed<br />Solutions<br />Research Institutions<br />Poor Farmers<br />Universities<br />Donors<br />Identified Need<br />Potential <br />Solutions<br />Innovation<br />
  18. 18. How do we do business? <br /><ul><li>Ethical positioning of a charity
  19. 19. Operational drive and methodology of a company
  20. 20. Support and networking of an International Private Public Partnership
  21. 21. Market driven, establishing value chains</li></ul>We opened our doors in November 2005<br />
  22. 22. What are our Priority diseases?<br />Cattle<br />East Coast Fever<br />Contagious Bovine Pleuropneumonia<br />Hemorrhagic septicaemia<br />Trypanosomiasis<br />Sheep and goats<br />Peste des petits ruminants<br />Contagious caprine pleuropneumonia<br />Sheep & goat pox<br />Pigs<br />Porcine cysticercosis<br />African swine fever<br />Classical swine fever<br />Poultry<br />Newcastle disease<br />Highly pathogenic Avian Influenza <br />Multi-species<br />Rift Valley fever<br />
  23. 23. Current Programmes<br />Trypanosomosis Programme<br />VACNADA Project<br />BMGF/DFID Project<br />Process focused on capacity building for at least 8 African labs, related to vaccines for:<br /><ul><li>CBPP
  24. 24. CCPP
  25. 25. PPR
  26. 26. ND</li></ul>(Kenya, Ethiopia, Ghana, Mali, Senegal, DRC, Botswana, Cameroon)<br />1- Regulatory Process<br />2- Rift Valley Fever<br />3- East Coast Fever<br />4- Porcine cysticercosis<br />5- Newcastle disease<br />6- Intellectual Property<br />African animal trypanosomosis:<br /><ul><li> Vaccine
  27. 27. Medication
  28. 28. Diagnostics
  29. 29. Clinical trials</li></ul>7- Contagious bovine pleuropneumonia<br />8- Contagious caprinepleuropneumonia<br />9- Peste des petits ruminants<br />
  30. 30. Current partnership: 128<br />Legal agreements:<br />82<br />(+ 45 in preparation)<br />
  31. 31. Intellectual Assets<br />The main purpose of GALVmed’s IA<br />management is to ensure that Global Access is achieved<br />Ensuring that our investments into projects and technologies do<br />benefit the poor farmers for whom livestock is a lifeline<br />The risk we face if we fail to do properly manage IA<br />– Lack of control of the fruits of our own investments, others reap the benefits<br />– In the long run we fail to achieve our objectives<br />– Weakening organizational strength<br />
  32. 32. Self-determination through livestock<br />“I was so poor after my husband died that I was almost a beggar……. <br />Today I am confident and earn money daily - I am a community animal health worker. I have 12 goats, several chickens and I’ve just bought a donkey to carry water. <br />My children are all at school and I am hoping my eldest boy will become a doctor. I don’t need a husband to support me now.”<br />Teresa Ndege- Kenyaa<br />
  33. 33.
  34. 34. Thank You!<br />
  35. 35. Presented at Business - Sharing Value? <br />20thSeptember 2011, Edinburgh<br />A NIDOS event<br />